US Medicare MFN Drug Pricing Could Raise Global Costs, Delay Launches: Lancet Study

A Lancet modelling study indicates that US Medicare Most-Favored-Nation drug pricing would cut US brand-name drug spending but may push manufacturers to raise prices or delay launches in other markets. The finding highlights a potential policy trade-off between US fiscal savings and global access, though the study is model-based and not empirical.